Show simple item record

dc.contributor.authorNieder, Carsten
dc.contributor.authorDalhaug, Astrid
dc.contributor.authorPawinski, Adam
dc.date.accessioned2020-06-29T13:55:42Z
dc.date.available2020-06-29T13:55:42Z
dc.date.issued2019-01
dc.description.abstract<p><i>Background/Aim - </i>The aim of this study was to analyze the prognostic impact of serum lactate dehydrogenase (LDH) in patients with oligometastatic brain metastases, arbitrarily defined as max. Four brain lesions and 5 metastatic lesions overall. <p><i>Patients and Methods - </i>This was a retrospective single institution analysis. Overall, 42 patients were identified from a prospectively maintained database. <p><i>Results - </i>Seventeen patients (40%) had extracranial metastases. Twelve patients (29%) had elevated LDH (≥255 U/l). Their median survival was significantly shorter than that of patients with normal LDH. Due to an interaction with performance status, this result was separately confirmed in patients with performance status ≥70. <p><i>Conclusion - </i>Oligometastatic disease is not always correctly diagnosed, because all radiological modalities are limited by certain thresholds for detection of small metastases. We hypothesize that LDH is associated with survival, because this biomarker may reflect the total burden of malignant disease. Future studies should examine whether or not ablative local treatment of oligometastases is warranted in patients with elevated LDH.en_US
dc.identifier.citationNieder C, Dalhaug A, Pawinski A. Serum lactate dehydrogenase contributes to prognostic assessment in patients with oligometastatic cancer and brain involvement. In Vivo. 2019;33(1):229-232en_US
dc.identifier.cristinIDFRIDAID 1690674
dc.identifier.doi10.21873/invivo.11464
dc.identifier.issn0258-851X
dc.identifier.issn1791-7549
dc.identifier.urihttps://hdl.handle.net/10037/18684
dc.language.isoengen_US
dc.publisherInternational Institute of Anticancer Researchen_US
dc.relation.journalIn Vivo
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserveden_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.titleSerum lactate dehydrogenase contributes to prognostic assessment in patients with oligometastatic cancer and brain involvementen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record